Milestone Pharmaceuticals Inc.
MIST
$2.15
$0.073.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.55% | 29.43% | 127.37% | 0.72% | -34.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.01% | 29.69% | 95.90% | -10.52% | -37.40% |
| Operating Income | -23.01% | -29.69% | -95.90% | 10.52% | 37.40% |
| Income Before Tax | -26.31% | -38.48% | -100.51% | 9.17% | 37.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.31% | -38.48% | -100.51% | 9.17% | 37.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.31% | -38.48% | -100.51% | 9.17% | 37.41% |
| EBIT | -23.01% | -29.69% | -95.90% | 10.52% | 37.40% |
| EBITDA | -23.07% | -29.75% | -96.17% | 10.54% | 37.46% |
| EPS Basic | 13.32% | -38.02% | -51.74% | 41.00% | 59.36% |
| Normalized Basic EPS | 13.36% | -38.12% | -51.78% | 40.99% | 59.37% |
| EPS Diluted | 13.32% | -38.02% | -51.74% | 41.00% | 59.36% |
| Normalized Diluted EPS | 13.36% | -38.12% | -51.78% | 40.99% | 59.37% |
| Average Basic Shares Outstanding | 45.78% | 0.32% | 32.16% | 53.90% | 54.03% |
| Average Diluted Shares Outstanding | 45.78% | 0.32% | 32.16% | 53.90% | 54.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |